<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81761">
  <stage>Registered</stage>
  <submitdate>15/12/2006</submitdate>
  <approvaldate>22/12/2006</approvaldate>
  <actrnumber>ACTRN12606000535572</actrnumber>
  <trial_identification>
    <studytitle>Phase II Study of CUV1647 in Erythropoietic Protoporphyria (EPP)</studytitle>
    <scientifictitle>A Multicentre, Phase II, Open Label Study to Evaluate the Safety of CUV1647 and to Evaluate the Effect of Subcutaneous Implants of CUV1647 on the Time to Artificially Provoked Symptoms in Patients with Erythropoietic Protoporphyria (EPP)</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Erythropoietic Protoporphyria (EPP)</healthcondition>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Other metabolic and endocrine disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>CUV1647 (20 mg implant) every two months for a total of 12 months.  Patients will serve as their own contols for all tested parameters.</interventions>
    <comparator>No comparator.</comparator>
    <control>Historical</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to appearance of artificially provoked symptoms when hands are exposed to light from a solar simulator</outcome>
      <timepoint>At baseline and then every two months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Amount of rescue medication used to treat phototoxic reactions.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes is skin melanin density</outcome>
      <timepoint>From baseline to 2, 4, 6, 8, 10 and 12 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life as measured by SF36v2 </outcome>
      <timepoint>At baseline and again at 12 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number and severity of phototoxic reactions</outcome>
      <timepoint>Recorded over the 12 month study period.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with EPP (confirmed by elevated free protoporphyrin in peripheral erythrocytes and/or ferrochelatase mutation)- Fitzpatrick skin types I to IV.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Any other photodermatosis such as polymorphic light eruption (PLE), discoid lupus erythematosus (DLE) or solar urticaria- females who are pregnant, lactating or of child bearing age not using adequate methods of contraception- Any evidence of clinically significant organ dysfunction or any clinically significant deviation from normal in the clinical or laboratory determinations.- Acute history of drug or alcohol abuse (in the last 12 months).- History of disorders of the gastrointestinal, hepatic, renal, cardiovascular, respiratory, endocrine, neurological, haematological or systemic disease judged to be clinically significant by the Investigator.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Not applicable</concealment>
    <sequence>Not applicable</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/09/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Clinuvel Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Clinuvel Pharmaceuticals Limited</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Not applicable</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is intended to determine if CUV1647 can increase the tolerance of patients with EPP to sunlight and improve their quality of life.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Triemli Hospital-Zurich Canton Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>3/07/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Swaziland</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Elisabeth Minder</name>
      <address>Chefärztin Zentrallabor
Stadtspital Triemli
CH-8063 Zürich</address>
      <phone>+41 44 4662320</phone>
      <fax>+41 44 4662744</fax>
      <email>Elisabeth.Minder@triemli.stzh.ch</email>
      <country>Switzerland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Dennis Wright</name>
      <address>Level 13
1 Collins Street
Melbourne VIC 3000</address>
      <phone>+61 3 96604900</phone>
      <fax>+61 3 96604999</fax>
      <email>dennis.wright@clinuvel.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>